Status:

COMPLETED

Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism

Lead Sponsor:

University of Ottawa

Conditions:

Major Depression

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

Reduction of volume of the hippocampus has been associated with major depression in many studies. It has been suggested that antidepressants may protect against hippocampus volume loss in humans assoc...

Detailed Description

Individuals who are defined as having treatment-resistant major depression (failure of at least 2 trials of an antidepressant at an adequate dose) and currently meet DSM-IV criteria for depression qua...

Eligibility Criteria

Inclusion

  • Male or female between ages of 18 to 65 years of age.
  • A diagnosis of Major Depression according to the DSM-IV criteria
  • Failing to achieve remission while receiving at least two different antidepressants at adequate dosage for at least 6 weeks.
  • Initial score of at least 18 on the HAMD-17 item rating scale

Exclusion

  • A diagnosis of substance abuse or dependence in the last 6 months or a lifetime diagnosis of substance abuse according to the DSM-IV criteria, elicited by inquiry.
  • A diagnosis of post-traumatic stress disorder, schizophrenia, schizo-affective disorder and other psychotic disorders, anorexia nervosa or a history of a manic or mixed episode
  • Major medical illnesses including endocrine and neurological disorders, as well as a history of significant head trauma
  • Exposure to oral or intravenous steroids
  • Contraindications to magnetic resonance imaging
  • An IQ less than 80

Key Trial Info

Start Date :

February 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT00704860

Start Date

February 1 2005

End Date

December 1 2010

Last Update

January 19 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Ottawa Institute of Mental Health Research

Ottawa, Ontario, Canada, K1Z 7K4

Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism | DecenTrialz